Evolus, Inc. (EOLS) Estados Financieros e Histórico

Evolus, Inc. (EOLS) — Precio $7.99 HealthcareDrug Manufacturers - Specialty & Generic — NASDAQ

Últimos resultados publicados:

Estados financieros detallados de Evolus, Inc. (EOLS): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.

Resumen del Análisis

Evolus, Inc. registró ingresos de $297.2M en el último ejercicio fiscal, con un CAGR de 5 años del 39.4%.

Márgenes de los últimos 12 meses: margen bruto 66.2%, margen operativo -7.3%, margen neto -10.8%.

Al precio actual de $7.99, EOLS presenta beneficios negativos (P/E no significativo) y un ROE del 123.11%. La capitalización bursátil es de $526M.

Cuenta de Resultados (10 años)

Año2016201720182019202020212022202320242025
Ingresos000$34.9M$56.5M$99.7M$148.6M$202.1M$266.3M$297.2M
Coste de Ventas$326000$218000$9000$8.0M$18.3M$43.5M$58.8M$61.6M$84.0M$104.4M
Beneficio Bruto-$326000-$218000-$9000$26.9M$38.2M$56.1M$89.8M$140.5M$182.3M$192.8M
I+D$12.6M$6.7M$6.5M$4.0M$1.7M$2.1M$6.7M$15.4M$9.2M$9.6M
Generales y Administrativos$7.0M$4.8M$29.1M$113.6M$98.2M$112.1M$141.8M$164.9M$198.0M$220.8M
Gastos Operativos$20.0M$11.7M$35.6M$125.9M$191.3M$100.5M$155.1M$189.8M$216.7M$230.4M
Beneficio Operativo-$20.0M-$11.7M-$46.1M-$98.9M-$153.1M-$44.4M-$65.3M-$49.2M-$34.4M-$37.6M
EBITDA-$19.6M-$11.5M-$46.1M-$92.1M-$144.8M-$39.1M-$53.9M-$41.8M-$25.0M-$22.5M
Gastos por Intereses00$863000$8.0M$10.5M$1.4M$9.1M$13.8M$18.7M$19.7M
Beneficio Antes de Impuestos-$20.0M-$11.7M-$46.8M-$105.1M-$162.9M-$46.8M-$74.3M-$61.5M-$49.8M-$51.0M
Impuestos$93000-$7.3M$65000-$15.0M$77000$42000$95000$176000$664000$677000
Beneficio Neto-$20.1M-$4.5M-$46.9M-$90.0M-$163.0M-$46.8M-$74.4M-$61.7M-$50.4M-$51.6M
BPA$-1.08$-0.19$-1.92$-3.19$-4.83$-0.94$-1.33$-1.08$-0.81$-0.80
BPA Diluido$-1.08$-0.19$-1.92$-3.19$-4.83$-0.94$-1.33$-1.08$-0.81$-0.80
Acciones en Circulación (Diluidas)$18.6M$23.6M$24.4M$28.2M$33.7M$49.8M$56.1M$56.9M$62.0M$64.5M

Cuenta de Resultados (Trimestral)

Año2025-Q32025-Q42026-Q12026-Q2
Ingresos$69.0M$90.3M$73.1M$84.1M
Beneficio Bruto$45.8M$59.3M$47.4M$57.2M
Beneficio Operativo-$11.5M-$291000-$6.9M-$4.5M
EBITDA-$9.5M$7.1M-$3.8M-$4.0M
Beneficio Neto-$15.7M$130000-$10.7M-$8.1M
BPA$-0.24$0.00$-0.16$-0.12
BPA Diluido$-0.24$0.00$-0.16$-0.12

Balance (10 años)

Año2016201720182019202020212022202320242025
Caja y Equivalentes00$93.2M$109.9M$102.6M$146.3M$53.9M$62.8M$87.0M$53.8M
Inversiones a Corto000$19.9M$5.0M00000
Cuentas por Cobrar0$72.6M0$10.7M$9.7M$14.7M$22.4M$30.5M$47.7M$54.7M
Inventario000$6.4M$3.4M$1.8M$18.9M$11.0M$12.2M$27.0M
Activos Corrientes$211000$72.8M$94.3M$152.2M$127.6M$178.8M$100.8M$112.4M$151.3M$142.9M
Inmovilizado Material000$5.0M$4.7M$4.1M$4.6M$7.8M$10.4M$12.5M
Fondo de Comercio$21.2M$21.2M$21.2M$21.2M$21.2M$21.2M$21.2M$21.2M$21.2M$21.2M
Activos Intangibles$56.1M$56.1M$56.1M$59.6M$55.3M$50.6M$48.6M$47.1M$48.8M$48.0M
Activos Totales$77.5M$152.2M$171.8M$240.4M$209.1M$257.5M$178.0M$189.0M$232.6M$225.9M
Cuentas por Pagar$2.9M$445000$1.6M$5.8M$9.6M$6.1M$8.9M$4.3M$9.2M$23.4M
Deuda a Corto$59.8M$211.3M00$93.5M00000
Pasivos Corrientes$63.3M$212.7M$5.3M$24.4M$180.2M$57.7M$46.5M$48.3M$63.0M$75.3M
Deuda a Largo00$16.9M$91.5M$40.5M$71.2M$71.9M$120.4M$121.5M$146.1M
Pasivos Totales$84.6M$227.8M$87.5M$161.0M$282.0M$175.6M$159.5M$209.7M$227.0M$249.0M
Reservas-$66.8M-$75.5M-$123.0M-$213.1M-$376.1M-$422.9M-$497.3M-$559.0M-$609.4M-$661.0M
Patrimonio Neto-$7.1M-$75.5M-$123.0M$79.5M-$73.0M$81.9M$18.5M-$20.7M$5.5M-$23.1M
Deuda Total$59.8M$211.3M$16.9M$96.5M$138.3M$74.7M$74.4M$126.5M$130.0M$155.0M
Deuda Neta$59.8M$211.3M-$76.3M-$33.3M$30.8M-$71.5M$20.5M$63.7M$43.0M$101.2M
Capital Circulante-$63.1M-$139.9M$89.1M$127.8M-$52.6M$121.1M$54.3M$64.1M$88.4M$67.6M

Balance (Trimestral)

Año2025-Q32025-Q42026-Q12026-Q2
Caja y Equivalentes$43.5M$53.8M$49.8M$45.2M
Activos Totales$219.0M$225.9M$220.6M$248.0M
Pasivos Totales$247.8M$249.0M$249.4M$278.9M
Patrimonio Neto-$28.8M-$23.1M-$28.8M-$30.9M
Deuda Total$154.9M$155.0M$164.9M$164.8M

Flujo de Caja (10 años)

Año2016201720182019202020212022202320242025
Beneficio Neto-$20.1M-$4.5M-$46.9M-$90.0M-$163.0M-$46.8M-$74.4M-$61.7M-$50.4M-$51.6M
Amortizaciones$326000$218000$9000$5.0M$7.7M$6.3M$4.5M$5.9M$6.0M$8.7M
Compensación en Acciones$957000$586000$7.0M$9.5M$10.6M$9.6M$10.8M$16.5M$22.3M$20.7M
Cambio en Capital Circulante$5.4M-$2.1M$2.8M-$20.8M$35.6M-$11.5M-$34.3M-$5.9M-$6.6M-$22.5M
Flujo de Caja Operativo-$13.3M-$13.0M-$25.7M-$93.4M-$57.9M-$33.4M-$84.9M-$34.0M-$18.0M-$42.3M
Inversiones (CapEx)00-$9000-$4.6M-$3.1M-$970000-$2.9M-$1.6M-$1.5M-$8.5M
Adquisiciones000$4.2M$2.3M00000
Recompra de Acciones0000000000
Dividendos Pagados0000000000
Flujo de Caja Libre-$13.3M-$13.0M-$25.7M-$98.0M-$61.0M-$34.4M-$87.9M-$35.6M-$19.5M-$50.7M

Flujo de Caja (Trimestral)

Año2025-Q32025-Q42026-Q12026-Q2
Flujo de Caja Operativo-$14.7M$12.8M-$10.0M-$3.6M
Inversiones (CapEx)-$2.2M-$2.2M-$1.7M$1.2M
Flujo de Caja Libre-$16.8M$10.7M-$11.6M-$2.4M
Dividendos Pagados0000
Compensación en Acciones$5.1M$5.1M$5.1M$5.6M

Crecimiento y Márgenes (10 años)

Año2016201720182019202020212022202320242025
Crecimiento Ingresos (anual)+61.9%+76.3%+49.1%+36.0%+31.8%+11.6%
Crecimiento Beneficio Neto (anual)+77.7%-946.1%-92.1%-81.1%+71.3%-59.0%+17.1%+18.3%-2.4%
Crecimiento BPA (anual)+82.4%-910.5%-66.1%-51.4%+80.5%-41.5%+18.8%+25.0%+1.2%
Cambio en Acciones (anual)+26.9%+3.4%+15.7%+19.5%+47.5%+12.6%+1.5%+9.0%+4.0%
Crecimiento FCF (anual)+1.7%-97.0%-281.5%+37.7%+43.7%-155.7%+59.4%+45.4%-160.5%
Margen Bruto77.1%67.6%56.3%60.4%69.5%68.5%64.9%
Margen Operativo-283.3%-270.7%-44.6%-44.0%-24.4%-12.9%-12.7%
Margen EBITDA-263.7%-256.0%-39.2%-36.2%-20.7%-9.4%-7.6%
Margen Neto-257.8%-288.3%-47.0%-50.1%-30.5%-18.9%-17.4%
Margen FCF-280.5%-107.9%-34.5%-59.1%-17.6%-7.3%-17.1%
Tasa Impositiva Efectiva-0.5%61.8%-0.1%14.3%-0.0%-0.1%-0.1%-0.3%-1.3%-1.3%

Datos por Acción (10 años)

Año2016201720182019202020212022202320242025
FCF por Acción$-0.71$-0.55$-1.05$-3.47$-1.81$-0.69$-1.57$-0.63$-0.31$-0.79
Dividendo por Acción$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Acciones en Circulación (Básicas)$18.6M$23.6M$24.4M$28.2M$33.7M$49.8M$56.1M$56.9M$62.0M$64.5M

Qué mirar en Salud / Farma

El pipeline de I+D es el activo invisible. Patentes que caducan = ingresos que evaporan. Mira innovación y flujo de caja.

Rentabilidad

Rentabilidad sobre capital123.11%
Rentabilidad sobre capital invertido-15.27%
Rentabilidad sobre activos-13.84%
Margen bruto66.25%
Margen operativo-7.33%
Margen neto-10.85%

Salud financiera

Deuda / Patrimonio-5.33
Ratio corriente1.70
Piotroski F-Score2
Altman Z-Score-1.94

Ratios Clave (10 años)

Año2016201720182019202020212022202320242025
P/E-10.65-60.53-6.20-3.82-0.70-6.93-5.65-9.75-13.63-8.31
P/VC-30.09-3.59-2.364.33-1.553.9622.76-28.97123.99-18.55
P/V0.000.000.009.842.003.252.832.972.571.44
Margen Bruto0.0%0.0%0.0%77.1%67.6%56.3%60.4%69.5%68.5%64.9%
Margen Operativo0.0%0.0%0.0%-283.3%-270.7%-44.6%-44.0%-24.4%-12.9%-12.7%
Margen Neto0.0%0.0%0.0%-257.8%-288.3%-47.0%-50.1%-30.5%-18.9%-17.4%

Empresas relacionadas: AUTL · CBLL · EHAB · KIDS · KMDA · NGNE · QSI

Explorar sector: Healthcare · Drug Manufacturers - Specialty & Generic

Más secciones de EOLS: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos

Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones